Phosphorylation of serine 349 of p62 in Alzheimer’s disease brain by unknown
Tanji et al. Acta Neuropathologica Communications 2014, 2:50
http://www.actaneurocomms.org/content/2/1/50RESEARCH Open AccessPhosphorylation of serine 349 of p62 in
Alzheimer’s disease brain
Kunikazu Tanji1*, Yasuo Miki1, Taku Ozaki2, Atsushi Maruyama3, Hidemi Yoshida4, Junsei Mimura3,
Tomoh Matsumiya4, Fumiaki Mori1, Tadaatsu Imaizumi4, Ken Itoh3, Akiyoshi Kakita5, Hitoshi Takahashi6
and Koichi Wakabayashi1Abstract
Background: Extensive research on p62 has established its role in oxidative stress, protein degradation and in
several diseases such as Paget’s disease of the bone, frontotemporal lobar degeneration and amyotrophic
lateral sclerosis. Importantly, previous studies showed that p62 binds directly to Keap1, which is a ubiquitin E3
ligase responsible for degrading Nrf2. Indeed, colocalisation of p62 and Keap1 occurs in tumorigenesis and
neurodegeneration. A serine (S) residue in the Keap1-interacting region of p62 is phosphorylated in hepatocellular
carcinoma, and this phosphorylation contributes to tumour growth through the higher affinity of p62 to Keap1.
However, it remains largely unknown whether p62 is phosphorylated in the Keap1-interacting region under
neurodegenerative conditions.
Results: To answer this question, we generated an antibody against phosphorylated S349 (P-S349) of p62 and
showed that S349 is phosphorylated following disruption of protein degradation. In particular, the ratio of P-S349 to
total p62 levels was significantly increased in the brains with Alzheimer’s disease (AD) compared with controls. We also
compared the reactivity of the P-S349 antibody with P-S403 of p62 and showed that these two phosphorylated sites
on p62 cause different responses with proteasome inhibition and show distinct localisation patterns in AD brains. In
addition to disruption of protein degradation systems, activation of oxidative stress can induce P-S349.
Conclusion: These results support the hypothesis that disruption of protein degradation systems and sustained
activation of the Keap1-Nrf2 system occur in the brains with AD.
Keywords: Alzheimer’s disease, Autophagy, Cytoplasmic inclusion, Keap1, Oxidative stress, p62/SQSTM1/
sequestosome 1, Phosphorylation, ProteasomeIntroduction
Accumulation of misfolded or abnormally modified
proteins is a major characteristic of many neurodegen-
erative diseases and is largely attributed to aging, oxi-
dative stress, and genetic and environmental factors.
Additionally, protein aggregates can occur in any situ-
ation causing intracellular disruption of the protein
degradation system. Two major systems for protein
degradation exist in mammals, the autophagy-lysosome
system and the ubiquitin-proteasome system. Both sys-
tems cooperatively play an important role in intracellular* Correspondence: kunikazu@cc.hirosaki-u.ac.jp
1Department of Neuropathology, Institute of Brain Science, Hirosaki
University Graduate School of Medicine, 5 Zaifu-cho, Hirosaki 036-8562,
Japan
Full list of author information is available at the end of the article
© 2014 TANJI et al.; licensee BioMed Central L
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.protein degradation in the brain. Further studies using a
brain-specific deletion of each system have shown that
mice exhibit neurological deficits with age and that mis-
folded proteins are accumulated in neurons [1,2].
p62/SQSTM1/sequestosome 1 (referred to as p62) is a
multifunctional protein that is highly involved in protein
degradation. p62 contains a ubiquitin-associated (UBA)
domain at the C-terminus, thereby interacting with ubi-
quitinated and misfolded proteins [3,4]. Additionally,
p62 binds to one of the proteasomal subunits, regula-
tory particle 1 (Rpt1), through Phox and Bem1p (PB1)
domains at the N-terminus [5]. In addition, p62 inter-
acts with the autophagy-related gene (ATG) 8 family
[6], which is essential to autophagosomal formation [7].
Because of its unique properties, it has been suggestedtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Summary of human subjects
Case no. Pathologic diagnosis Age, y Gender PMI, h
1 AD 79 M 4
2 AD 86 F 4
3 AD 89 F 4
4 AD 81 F 4
5 AD 87 F 3
6 AD 87 F 3
7 AD 100 F 3
8 AD 104 F 3.5
9 control 71 M 1.5
10 control 76 M 3.2
11 control 82 F 4.5
12 control 71 M 1.5
13 control 75 M 1
14 control 64 M 3
15 control 62 M 9
16 control 82 M 2
AD, Alzheimer’s disease; PMI, postmortem interval.
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ubiquitinated and misfolded proteins for proteasomal
and autophagic degradation. Importantly, because p62
itself is degraded by autophagy [8], increased levels of the
p62 protein suggests that autophagic flux is impaired.
Recently, we assessed the level of p62 in the brains of
patients with neurodegenerative dementia, Alzheimer’s
disease (AD) and dementia with Lewy bodies (DLB), and
showed that the level of p62 was significantly increased
in the brains of patients with AD relative to controls
[9,10]. Furthermore, consistent with previous reports
[11-13], several genes related to the stress response and
detoxification were also increased in the brains with AD
compared with controls. Interestingly, recent studies
have shown that p62 binds directly to Keap1 [14-17],
which functions as a stress sensor through regulation of
NF-E2 related factor 2 (Nrf2) [18]. p62 is reported to be
one of the Nrf2-target genes and was also identified as
an antioxidant-responsive gene [15,19]. These findings
suggest a tight relationship between stress responses
and protein degradation dysfunction.
In this study, we focused on the binding region of
p62 with Keap1 (amino acids 344–356 of human p62).
Notably, Hancock et al. and Ichimura et al. demonstrated
that phosphorylation of serine 349 (S349) enhanced the
binding affinity between Keap1 and p62 [20,21]. However,
it remains unclear whether this phosphorylation occurs in
neurodegenerative conditions. Here, we generated an anti-
body specific to S349 of p62 and demonstrated that S349
was phosphorylated in the brains of patients with AD,
with levels significantly higher in AD relative to controls.
Further studies showed that S349 on p62 was phosphory-
lated upon disruption of the protein degradation systems
and exposure to sustained oxidative stress.
Materials and methods
Primary antibodies
For generation of antibodies against phosphorylated p62
at S349, rabbits were immunised with a synthetic pep-
tide based on residues 344–354 of human p62 with
phosphorylated S349 (P-S349), conjugated at the amino
terminus by an additional cysteine to keyhole limpet
hemocyanine together with adjuvants. Antisera were
purified by obtaining flow-through fractions from a col-
umn conjugated with p62 peptide. Phosphorylated p62
was characterised by ELISA by plating immunogen
peptide in multiwell plates. To demonstrate specificity,
the rabbit antisera against P-S349 were pre-absorbed
with phosphorylated peptide. After centrifugation, the
supernatant was filtered and used for experiments. For
immunohistochemical studies, treatment with alkaline
phosphatase (NEB, Beverly, MA, USA) was also per-
formed before incubation with the primary antibody.
An anti-p62 antibody specific to phosphorylation atS403 of human p62 was purchased from Millipore
(Bedford, MA, USA) [22].
Subjects
Tissue samples were obtained from the Department of
Neuropathology, Institute of Brain Science, Hirosaki
University Graduate School of Medicine, Hirosaki, and
the Department of Pathology, Brain Research Institute,
University of Niigata, Niigata, Japan. Written informed
consent for autopsy, collection of samples and subse-
quent analysis was obtained from the next of kin of the
deceased involved in this study. This study was approved
by the Committee of Medical Ethics of Hirosaki University
Graduate School of Medicine, Hirosaki, Japan. Brain tis-
sues from patients with AD (n = 8) and normal controls
(n = 8) were used (Table 1). The diagnoses had been con-
firmed by neuropathological examinations using immuno-
histochemistry for phosphorylated tau and amyloid β.
Cell cultures and treatment
SH-SY5Y human neuroblastoma (ECACC, Salisbury,
Wiltshire, UK) and HeLa (JCRB, Osaka, Japan) cells were
maintained in Dulbecco’s modified Eagle’s medium sup-
plemented with 10% fetal calf serum and antibiotics.
Cells were treated with epoxomicin (Calbiochem, San
Diego, CA, USA), MG132 (Calbiochem), bortezomib
(Cell Signaling Technology, Inc., Danvers, MA, USA),
bafilomycin A (Wako, Osaka, Japan), and amyloid β
peptide 1–40 or 1–42 (Aβ40 or Aβ42) (Peptide Institute
Inc., Osaka, Japan). For activation of the Nrf2 system, di-
ethyl maleate (DEM) was used at 100 μM. At the indicated
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saline (PBS) (pH 7.4), harvested and used as samples for
further studies.
Human p62 cDNA was prepared as previously described
[23]. p62 cDNA was subcloned into pcDNA3 (Invitrogen,
Carlsbad, CA, USA) tagged with hemagglutinin (HA) or
pEGFP-N1 (Invitrogen). Mutagenesis was performed ac-
cording to the manufacturer’s instructions (Takara, Otsu,
Japan), followed by sequencing to confirm the mutation
site. Serine (S) was changed into glutamic acid (E) for a
phosphorylation-mimetic mutant, or into alanine (A) for a
phosphorylation-deficient mutant. Cells were transfected
using Fugene 6 (Roche Molecular Biochemicals, Indian-
apolis, IN, USA) or Lipofectamine 2000 (Invitrogen).
siRNAs were purchased from Dharmacon (Lafayette,
CO, USA). The siRNAs (final concentration 20 nM) for
p62 (5’-GCA TTG AAG TTG ATA TCG A-3’), Keap1
(M-012453-00-0005), and Nrf2 (M-003755-02-0005)
were performed using Lipofectamine RNAi MAX (Invitro-
gen). After 24 h, the cells were treated with an inhibitor
for an additional 24 h. Cells were subsequently harvested
and lysed with lysis buffer [75 mM Tris–HCl, pH 6.8,
4% sodium dodecyl sulphate (SDS), 25% glycerol, 5% β-
mercaptoethanol].
Staining for tissues and cultured cells
For routine histological examination, the brains were
fixed with 10% buffered formalin for 3 weeks. Blocks
were cut from various cortical and subcortical regions,
embedded in paraffin, sectioned, and then stained with
hematoxylin and eosin. For immunohistochemistry, 4-
μm-thick sections were cut from the frontal and tem-
poral neocortex and hippocampus of patients with AD
and controls. The sections were dehydrated and pre-
treated with 0.25% potassium permanganate for 15 min,
then 2% oxalic acid for 3 min, followed by formic acid
for 10 min for rabbit anti-P-S349 and anti-P-S403 anti-
bodies. The sections were then subjected to immunohis-
tochemical processing using the avidin-biotin-peroxidase
complex method with diaminobenzidine (Sigma, Saint
Louis, MO, USA). The sections were counterstained
with hematoxylin.
Double immunofluorescent staining was performed
to detect overlapping expression of phosphorylated p62
and phosphorylated tau or Keap1. For this purpose, the
sections were blocked with donkey serum and then incu-
bated overnight at 4°C with a mixture of rabbit anti-
phosphorylated p62 and mouse anti-phosphorylated tau
(AT8; Innogenetics, Ghent, Belgium) or rat anti-Keap1.
On the next day, the sections were washed 5 times for
3 min each with PBS, followed by an incubation for 1 h
with Alexa Fluor 488- and 594-conjugated secondary
antibodies (Invitrogen). After a rinse with PBS, the
sections were mounted with Fluoromount G (SouthernBiotechnology Inc., Birmingham, AL, USA) and exam-
ined using a confocal microscope (EZ-Ci; Nikon, Tokyo,
Japan). Adobe Photoshop CS5 software (Adobe systems,
San Jose, CA, USA) was used for image processing.
After the cells were transfected with p62-EGFP wild-
type or mutants for 24 h, cultured cells were double-
immunolabelled with rabbit anti-phosphorylated p62
and mouse anti-p62 antibodies. Alexa Fluor 594- and
680-conjugated secondary antibodies (Invitrogen) were
used.
Fractionation of brain extracts
For biochemical analysis, brain tissues were dissected at
autopsy and rapidly frozen at −70°C. Frozen tissues
from the middle temporal cortex of patients with AD
(n = 3) and control subjects (n = 3) were weighed and
sequentially extracted with buffers of increasing detergent
strength using a previously described protocol [24]. Briefly,
samples were homogenised with 10 volumes of buffer A
(10 mM Tris–HCl, pH 7.5, 1 mM EGTA, 10% sucrose,
0.8 M NaCl) and centrifuged (fraction 1). Afterwards, an
equal volume of buffer A containing 2% Triton X-100 was
added. The samples were then incubated for 30 min at
37°C and centrifuged at 100,000 × g for 30 min at 4°C
(fraction 2). The resultant pellet was homogenised in 5
volumes of buffer A with 1% Sarkosyl and incubated for
30 min at 37°C. The homogenate was then centrifuged at
100,000 × g for 30 min at room temperature (fraction 3).
The Sarkosyl-insoluble pellet was homogenised in 4 vol-
umes of buffer A containing 1% 3-[(3-Cholamidopropyl)
dimethylammonio] propanesulfonate (CHAPS) (Sigma)
and centrifuged at 100,000 × g for 20 min at room
temperature (fraction 4). The pellet was sonicated in 0.2
volumes of 8 M urea buffer (fraction 5). The CHAPS-
soluble fraction (fraction 4) usually contains less total
protein than other fractions by this method. We applied
a constant volume of extract in each fraction to an SDS-
polyacrylamide gel electrophoresis (PAGE).
Immunoblot analysis
Frozen tissues form the middle temporal cortex of pa-
tients with AD (n = 8) and normal controls (n = 8) were
used in this study. Each tissue was weighed and homo-
genised with a 20-fold volume of lysis buffer described
above.
An equal amount of elution was subjected to SDS-
PAGE, and Western blot analysis was performed as previ-
ously described [23]. Horseradish peroxidase-conjugated
anti-mouse, anti-rat or anti-rabbit IgG (Santa Cruz Bio-
technology, Santa Cruz, CA, USA) was used as a second-
ary antibody. Detection was performed according to the
protocol provided with the ECL or ECL prime detection
system (Amersham Pharmacia Biotech, Piscataway, NJ,
USA). The data were quantified as described below and
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Keap1 (ProteinTech Group, Inc., Chicago, IL, USA), p62
(MBL, Nagoya, Japan), β-actin (Sigma), GFP (Invitrogen),
acetylated histone (Millipore) and LC3 (Sigma), and
mouse monoclonal antibodies against ubiquitin (FK1;
Millipore) and Aβ oligomer (6E10; Covance, Richmond,
CA, USA) were used in this study.
Proteasomal activity assay
Chymotryptic, tryptic, and caspase proteasome activities
were measured as described previously [25] with minor
modifications. SH-SY5Y neuroblastoma cells were washed
with PBS and pelleted by centrifugation. Cell pellets were
sonicated in homogenisation buffer [25 mM Tris (pH 7.5),
100 mM NaCl, 5 mM ATP, 0.2% (v/v) NP-40 and 20%
glycerol], and cell debris was removed by centrifugation at
4°C. Protein concentration in the resulting crude cellular
extracts was determined by the bicinchoninic acid method
(Pierce, Rockford, IL, USA). One hundred micrograms of
protein from crude cellular extracts of each sample was
diluted with buffer I [50 mM Tris–HCl (pH 7.4), 2 mM
dithiothreitol, 5 mM MgCl2, 2 mM ATP] to a final volume
of 0.5 mL (assayed in quadruplicate). Fluorogenic prote-
asome substrates were purchased from Boston Biochem
(Cambridge, MA, USA): Suc-LLVY-7-amido-4-methyl-
coumarin (AMC) (chymotrypsin-like peptidase activity),
Ac-RLR-AMC (trypsin-like peptidase activity), and Z-
LLE-AMC (caspase-like or peptidylglutamyl peptide-
hydrolysing activity). Each was dissolved in DMSO and
brought to a final concentration of 80 μM. Proteolytic
activities were assessed in 2 h at 25°C by measuring the
release of the fluorescent group AMC using a fluores-
cence plate reader (Fluoroskan Ascent, Thermo Scien-
tific, Waltham, MA, USA) with excitation and emission
wavelengths of 380 and 460 nm, respectively.
Dot blot analysis
We modified the filter-trap analysis as described previ-
ously [26]. Briefly, phosphorylated or non-phosphorylated
peptides were diluted with TBS (Tris–HCl, pH 7.5,
150 mM NaCl), and applied to a 0.22-μm cellulose acetate
membrane (Millipore) on a slot blot apparatus (Bio-
Rad, Hercules, CA, USA) using a vacuum manifold.
After washing with TBS containing 0.1% Triton X-100,
the membrane was incubated with anti-phosphorylated
p62 and pan-p62 antibodies and detected using the ECL
detection system as described above.
Quantitative analysis and statistical analysis
A semi-quantitative analysis of protein detection was
performed by image analysis using the Image J software
provided by the NIH. All of the values were represented
as the means + standard deviation (SD). The statistical
significance was evaluated using Student’s t-test whencomparing two conditions. A probability value of less
than 0.05 (p < 0.05) was considered to be significant.
Results
Specificity of antibodies against p62 phosphorylated at
serine 349
Recent papers reported that p62 binds to Keap1 through
residues 344–356, called the Keap1-interacting region
(KIR) (Figure 1a). This domain is conserved among spe-
cies (Figure 1b), and STGE regions are very similar to
the binding region (ETGE) of Nrf2 to Keap1. Because
serine can be phosphorylated, this is potentially true of
the serine within the STGE region of p62. To test this
hypothesis, we raised antibodies against a synthetic pep-
tide corresponding to amino acid residues 344–354 of
human p62 with a phosphorylated S349 residue. After ab-
sorbance with the antibody against non-phosphorylated
p62, ELISA and dot blot analysis confirmed that an anti-
body against phosphorylated p62 at S349 (referred to as
P-S349) specifically recognised the phosphorylated peptide
but not the non-phosphorylated peptide (Figure 1c). Simi-
larly, a recent study demonstrated that S403 of p62 can be
phosphorylated and that this phosphorylation strengthens
the affinity with polyubiquitin and ubiquitinated molecules
[22]. Therefore, we compared the reactivity of two anti-
bodies against phosphorylated p62 (P-S349 and P-S403) in
cultured cells treated with lysosome and proteasome
inhibitors. In cells treated with a lysosome inhibitor
(bafilomycin A), P-S349 and P-S403 signals increased
in a time-dependent manner (Figure 1d). In contrast,
after treatment with a proteasome inhibitor (epoxomi-
cin), P-S349 signals were clearly detected in samples
collected after 6 h, 12 h and 24 h, whereas P-S403 sig-
nals were faintly detected in samples collected after
12 h and 24 h. Quantitative intensity showed that the
rate of the P-S349-positive signal to total p62 clearly
increased in a time-dependent manner and that epoxo-
micin treatment more efficiently induced P-S349 than
bafilomycin A (Figure 1e, f ).
S349 is phosphorylated following proteolysis disruption
We further investigated the effect of several proteasomal
inhibitors on the phosphorylation of p62. P-S349 signals
were also induced in neuroblastoma and HeLa cells fol-
lowing treatment with the proteasome inhibitors epoxo-
micin, MG132 or bortezomib for 24 h (Additional file 1:
Figure S1). Immunoblotting showed that treatment with
epoxomicin for 60 min faintly induced P-S349. Addition-
ally, a proteasomal activity assay showed a significant de-
crease in trypsin-, chymotrypsin- and caspase-like activities
in cells treated with epoxomicin in a time-dependent man-
ner (Figure 2b).
p62 has been reported to be phosphorylated at S266,
T269 and S272, and these phosphorylations can change
Figure 1 Specificity of antibody against phosphorylated p62 at serine 349 (S349). (a) Schematic representation of human p62. Number of
amino acid is indicated. PB1, proteasomal binding region 1; ZnF, zinc finger; LIR, LC3-interacting region; KIR, Keap1-interacting region; UBA, ubiquitin
associated domain. (b) Alignment of the KIR in p62 homologues. Underline represents the epitope for the antibody against phosphorylated p62. (c)
Synthetic peptide (344–354 of human p62) was used to confirm the reactivity of phosphorylated p62-specific antibody by dot blot analysis.
Phosphorylated peptide (P-peptide) is diluted, applied to a membrane and detected with the antibody against p62 phosphorylated at S349
(P-S349), whereas non-phosphorylated peptide (NP-peptide) is not detected. (d) HeLa cells were treated with an autophagic inhibitor, bafilomycin A
(Baf), or a proteasome inhibitor, epoxomicin (Epo), for the indicated times. Two types of phosphorylation-specific antibodies differentially recognise p62
with phosphorylation on distinct residues. The molecular mass is indicated on the left side of the panel. (e, f) Quantitative data represents the ratio of
the P-S349 (e) or P-S403 (f) level relative to the total p62 level at the indicated times following Baf or Epo treatment.
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Figure 2 The effect of proteasome inhibitor on p62 phosphorylation in a shorter time. (a) SH-SY5Y cells were treated with Baf or Epo
for the indicated times. Simultaneously, proteasomal activity was assessed. Immunoblotting analysis shows that both inhibitors induced the
phosphorylation of S349 in a similar to HeLa cell. (b) A proteasomal activity assay shows that Epo inhibits trypsin-like, chymotrypsin-like and
caspase-like activities of the proteasome in a time-dependent manner. While, Baf inhibits these activities in the first 30 minutes, and thereafter
their activities returns to the basal levels.
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termine whether the phosphorylation of S349 can also
contribute to the cellular localisation of p62. Immuno-
fluorescence studies showed that p62 is weakly de-
tected in the cytoplasm of untreated SH-SY5Y cells
(Figure 3a) and that a positive signal for P-S349 was
not detected in these cells. After treatment with an au-
tophagy or proteasome inhibitor, p62 immunoreactivity
was enhanced and cytoplasmic bodies formed. Consist-
ent with the immunoblotting results, P-S349 signals
were enhanced and densely accumulated in cytoplasmic
inclusions in cells treated with the proteasome inhibitors
epoxomicin and bortezomib (Figure 3a). In contrast,
P-S403 signals were undetectable even in cytoplasmic
inclusions (Figure 3b). In cells treated with bafilomycin
A, P-S349 and P-S403 signals were broadly distributed
throughout the cytoplasm of the cells. Similar results
were observed in HeLa cells. Therefore, these data indi-
cate that P-S349 localises to cytoplasmic bodies, and
suggests that S349 phosphorylation is closely related to
the formation or degradation of cytoplasmic inclusions
after proteasomal disruption.S349 phosphorylation induces efficient formation of
cytoplasmic inclusions
To clarify the role of P-S349 in the formation of cyto-
plasmic inclusions, we compared wild-type p62 with a
phosphorylation-mimetic (S349E) or a phosphorylation-
defective (S349A) mutant. Immunocytofluorescence stud-
ies showed that the S349E mutant caused a higher number
of cytoplasmic inclusions compared with p62 wild-type
and the S349A mutant (Figure 4a). The anti-P-S349 anti-
body strongly detected the p62 S349E mutant, but only
weakly detected p62 wild-type and the S349A mutant.
This result was consistent with the result of immunoblot-
ting (Additional file 2: Figure S2). Epoxomicin treatment
increased this reaction and induced aggresomes, which
are localised near the nucleus [28]. Aggresomes were im-
munostained with histone deacetylase 6 antibody and were
also positive for P-S349 (data not shown), suggesting that
P-S349 enhances inclusion formation. Importantly, oxida-
tive stress also induced P-S349. We used DEM as a stress
inducer, which clearly induced the formation of cytoplasmic
inclusions and P-S349 signal (Figure 4b). In addition, Keap1
colocalised with P-S349 in the inclusions. During these
Figure 3 The localisation of phosphorylated p62 in cells. (a) The
effect of autophagy or proteasomal inhibitor on the localisation of
phosphorylated p62. Confocal immunofluorescence analysis shows
that p62 immunoreactivity is weakly observed in cells without
stimulation. After stimuli with autophagy or proteasome inhibitors,
p62 is primarily observed in the cytoplasm (green) and forms
cytoplasmic bodies. P-S349 on p62 (red) is undetectable in cells
without stimulation. After Baf treatment for 24 h, P-S349 is observed
throughout cells. In contrast, the P-S349 signal is concentrated in
cytoplasmic bodies after treatment with the proteasome inhibitors Epo
and bortezomib (BTZ). The islet panels indicate higher magnification.
(b) After Baf treatment for 24 h, the P-S403 signal is enhanced.
Proteasome inhibitors do not induce any signals of P-S403.
Scale bar = 20 μm.
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S349 after transfections using Fugene 6 and Lipofecta-
mine 2000 (Additional file 3: Figure S3). These results
were consistent with the immunoblotting showing thatLipofectamine 2000 clearly induced phosphorylation,
and DEM and Fugene 6 moderately induced phosphor-
ylation of p62 at S349 (Figure 4c).
We next examined the effect of disruption of the p62-
Keap1-Nrf2 complex on the phosphorylation of p62
(Figure 4d). Epoxomicin treatment enhanced the P-S349
signal in cells treated with control siRNA, whereas no
P-S349 signal was observed in cells subjected to sip62 or
siKeap1, and a weaker signal in cells treated with siNrf2
compared to controls. Knockdown experiments using
siRNA suggested that this phosphorylation is sensitive to
alteration of the tertiary structure of the p62-Keap1
complex. Collectively, these results indicate that p62 is
phosphorylated at S349 under several pathological con-
ditions and that phosphorylation at S349 efficiently
forms cytoplasmic inclusions, leading to a higher affinity
for Keap1.
S349 is phosphorylated in the brains with alzheimer’s
disease
We previously demonstrated that p62 and Keap1 are
colocalised in the cytoplasmic inclusions observed in the
brains of patients with neurodegenerative dementia
(neurofibrillary tangles in AD, and Lewy bodies in DLB
[10]). Additionally, higher levels of p62 are observed in
AD compared to controls. Therefore, we next deter-
mined whether phosphorylation of S349 and S403 oc-
curs in the brains of patients with AD and control
subjects using antibodies against phosphorylated p62.
Immunoblot analysis showed that anti-P-S349 and anti-
P-S403 antibodies recognised signals in the brains simi-
lar to those observed in cultured cells with an inhibitor
(Figure 5a). Notably, the signal intensity of P-S349 was
higher in AD compared with controls (Figure 5b), and
quantitative data showed that the ratio of the P-S349
level to actin was increased in AD relative to controls
(Figure 5c). The S403 level was unchanged between AD
and controls. Quantitative data showed that the ratio of
the P-S349 level to total p62 was also increased in AD
relative to controls (Figure 5d, e). The S403 level was
repressed in AD relative to controls.
Further studies were performed to determine whether
the phosphorylation of p62 alters its solubility. Frozen
samples were fractionated with detergents of increasing
strength and subsequently analysed by immunoblotting.
The P-S349 signal was primarily detected in detergent-
insoluble fractions (fraction 5) in controls and AD (top
panel in Figure 5f). In addition, detergent-soluble P-S349
was also present in fraction 3 in controls. However, it was
shifted to fraction 1 in AD. P-S403 signal was distributed
to fractions 1, 3 and 5 in AD and fractions 1 and 5 in con-
trols (the second top panel in Figure 5f). Because total p62
is primarily detected in fractions 3 and 5 in controls and
AD (the third top panel in Figure 5f), this suggests that
Figure 4 (See legend on next page.)
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Figure 4 The effect of phosphorylation-mimetic mutants on the formation of cytoplasmic inclusions in cells. (a) p62 wild-type and
mutants (S349E and S349A) fused with EGFP were transfected into HeLa cells. After 24 h, the cells were double-stained with rabbit anti-P-S349
(red) and mouse anti-pan-p62 (purple) antibodies. Wild-type p62 forms cytoplasmic inclusions in cells. The higher number of cytoplasmic inclusions is
observed in cells transfected with the phosphorylation-mimetic mutant (S349E) compared with cells containing p62 wild-type and the S349A mutant
(phosphorylation defective). An anti-phosphorylated p62 antibody reacts with S349E in inclusions, whereas this antibody only partially recognises
inclusions in cells with p62 wild-type and S349A. Epo treatment increases the formation of S349 inclusions and p62 accumulation. The islet panels
indicate higher magnification. Scale bar = 20 μm. (b) DEM also enhances the formation of p62 (blue) and phosphorylation of S349 (green). Keap1 (red)
also colocalised with P-S349 signals. The islet panels indicate higher magnification. Scale bar = 20 μm. (c) Cells were treated with or without DEM for
24 h, and with transfection reagent alone (Fugene 6 or Lipofectamine 2000). Cells were harvested and analysed by immunoblotting. P-S349 signals are
detected in samples treated with DEM (lane 2) and transfection reagents (lanes 4 and 5). (d) Knockdown of p62, Keap1 or Nrf2 was performed using
Lipofectamine RNAi MAX. After 24 h, cells were treated with Epo for 24 h and harvested. Epo treatment enhances the P-S349 signal in cells treated with
control siRNA compared to vehicle alone. No signals for P-S349 are observed in cells subjected to siRNA against p62 and siKeap1. Similar to other
transfection reagents, Lipofectamine RNAi MAX slightly induced the phosphorylation of p62 at S349 (lane 1).
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brains.
Based on these results, we hypothesise that an excess
of Aβ potentially influences the phosphorylation of p62
because Aβ can induce tau phosphorylation [29,30]. To
test this hypothesis, SH-SY5Y cells were treated with
Aβ40 or Aβ42 for 24 h. Although the levels of total p62
and an autophagosomal marker protein (LC3-II) were
increased following disruption of the protein degrad-
ation systems (Figure 6a), Aβ40 or Aβ42 did not induce
phosphorylation of p62 at S349 and S403. We further
treated cells with Aβ for an additional 48 h or 72 h.
However, no phosphorylation was induced (data not
shown). The proteasomal activity assay showed that epox-
omicin strongly inhibited trypsin-like, chymotrypsin-like
and caspase-like activities of the proteasome (Figure 6b).
Bafilomycin A mildly inhibited trypsin-like activity. Aβ40
and Aβ42 did not have any effect on proteasomal and
autophagic activities.
Neurofibrillary tangles are positive for P-S349
To investigate where P-S349 is localised in AD brains,
we performed immunohistochemical studies. The anti-
P-S349 antibody strongly immunolabelled neurofibrillary
tangles (NFTs) in AD (Figure 7a). Positive signals in
NFTs were abolished by alkaline phosphatase treatment.
In addition, absorption of the anti-P-S349 antibody with
phosphorylated peptide diminished the staining. Alter-
natively, the anti-P-S403 antibody weakly or moderately
stained dystrophic neurites in amyloid plaques (Figure 7b).
The anti-P-S403 antibody did not react with NFTs.
No immunoreactivity was observed in control sections
using both antibodies. A double-immunofluorescence
study confirmed the colocalisation of P-S349 and phos-
phorylated tau (Figure 7c) or Keap1 (Figure 7d).
Discussion
Under oxidative stress and certain pathological condi-
tions, the binding affinity of Keap1 for Nrf2 is decreased,
leading to the intranuclear shuttling of Nrf2 and thesubsequent increase of several types of genes, including
antioxidant and detoxifying enzymes. In our study, ex-
posure to oxidative stress (DEM) induced the phosphor-
ylation of p62 at S349 within KIR, which is the binding
region for Keap1. Total p62 levels are known to increase
by oxidative stress [31]. Because the phosphorylation of
S349 on p62 strengthens its affinity for Keap1 [20,21],
higher p62 levels and an increased affinity for Keap1
simultaneously occur under oxidative stress. In addition,
we showed that disruption of protein degradation sys-
tems can also induce the phosphorylation of S349. Al-
though S403 on p62 is also known to be phosphorylated
by inhibition of autophagic flux, proteasome inhibition
had less of an effect on the phosphorylation of S403 than
on S349. This result was also supported by immuno-
fluorescence showing that P-S349 signals were clearly
observed in the cytoplasmic inclusions of cultured cells.
In contrast, P-S403 signals were weakly detected in cyto-
plasmic inclusions. Because the phosphorylation of S403
likely enhances the affinity to ubiquitinated molecules
and helps degrade them by autophagy, it is possible that
P-S403 signals physiologically occur, but may be rela-
tively undetectable due to rapid self-degradation. By
contrast, p62 S394 is efficiently phosphorylated in re-
sponse to proteasome inhibition and exposure to oxi-
dative stress. Furthermore, even transfection reagents
can induce P-S394 immunoreactivity. These data sug-
gest that the ratio of the P-S394 level to total p62 may
be an indicator for noxious stimuli to cells.
Phosphorylation-mimetic mutations have been com-
monly used to investigate the role of phosphorylation.
Our specific antibody against P-S349 recognised the
phosphorylation-mimetic mutant p62 S349E. Immu-
nofluorescence showed that the S349E mutant had a
higher number of inclusions than p62 wild-type and
S349A, the latter being a phosphorylation-deficient mu-
tant. An anti-phosphorylated p62 antibody strongly de-
tected signals in cells with S349E, whereas it showed
partial reactivity in cellular inclusions with p62 wild-type
and S349A. Thus, it is likely that the phosphorylation of
Figure 5 (See legend on next page.)
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Figure 5 Phosphorylation of p62 in the brains of patients with AD. (a) Frozen tissues (the temporal cortex) of patients with AD and controls
were lysed and subjected to SDS-PAGE. HeLa cells were treated with Baf, and used as a positive control. P-S349 is detected in almost all patients
with AD but is only faintly detected in controls. The P-S403 signal is visible in all samples except for a control subject (case 6). An anti-oligomer
antibody detects smear bands in some patients with AD. The approximately 100 kDa bands appear to be non-specific (*). (b) The ratio of P-S349
or P-S403 levels against β-actin was measured. (c) Quantitative data show that the level of P-S349, but not of P-S403, is significantly increased in
AD compared with controls (*p < 0.01). The value in AD is defined as 100%. (d) The ratio of P-S349 or P-S403 levels against p62 was measured.
(e) The level of P-S403, but not of P-S349, is significantly decreased in AD compared with controls (*p < 0.05). (f) Frozen tissues were obtained
from the temporal cortex of patients with AD and control subjects (n = 3 in each group). Sequential biochemical fractionation shows that P-S349
is detected in fractions 1 and 5 (f1 and f5) in AD, and f3 and f5 in controls. Note that the signal is enhanced in f1 in AD samples compared with
controls. Instead, the signal is weaker in f5 of controls than that of AD samples. P-S403 is distributed in f1, f3 and f5 in AD, and f1 and f5 in controls.
Similar results are observed in other samples of AD and control cases. The CHAPS-soluble fraction (f4) has a lower quantity of proteins compared with
other fractions. Acetylated histone is used as one of the nuclear proteins. Non-specific (*).
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Nrf2 target genes are activated through the higher affin-
ity of Keap1 for p62 with P-S349, inclusion formation
itself exerts cyto-protective roles in the early stages of
this process.
Importantly, we showed that S349 on p62 is in fact
phosphorylated in the brains of patients with AD and that
the level was significantly increased in AD compared with
controls. Consistent with previous results [9,32], we alsoFigure 6 The effect of amyloid β (Aβ) on phosphorylated p62 levels.
or Epo. After 24 h, cells were harvested, lysed and analysed by immunoblo
P-S403 level is undetectable. In a sample treated with Baf, lipidated LC3 (LC
and P-S403 are undetectable due to the low level of total p62. (b) A prote
chymotrypsin-like and caspase-like activities of the proteasome. Baf mildly
proteasome activity and autophagic flux.demonstrated that the total p62 level was significantly in-
creased in AD relative to controls. The ratio of P-S349
levels to total p62 is significantly increased in AD relative
to controls. This suggests a disruption of protein degrad-
ation systems and/or the occurrence of oxidative stress in
the brains with AD, and the data also support previous
evidence demonstrating decreased proteasome activity
[11-13] and sustained oxidative stress occur in AD com-
pared with controls [33-35].(a) SH-SY5Y neuroblastoma cells were treated with Aβ40 or Aβ42, Baf
tting. Epo increases the levels of total p62 and P-S349, whereas the
3-II) is induced in a time-dependent manner, but signals for P-S349
asomal activity assay confirms that Epo inhibits trypsin-like,
inhibits these activities. However, Aβ40 and Aβ42 have no effect on
Figure 7 Immunohistochemical localisation of P-S349 and P-S403 in the brains of patients with AD. (a) Neurofibrillary tangles in the
entorhinal cortex. (b) Dystrophic neurites of senile plaques. (c) Colocalisation of P-S349 (green) and phosphorylated tau (red) in neurofibrillary tangles.
Bars = 50 μm. (d) Colocalisation of P-S349 (green) and Keap1 (red) in neurofibrillary tangles. Bars = 20 μm.
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deposition can induce phosphorylation of S349. Unex-
pectedly, however, we failed to find any significant
changes induced by Aβ40 or Aβ42 in our system. Anti-
Aβ oligomer antibody clearly showed positive signals in
cells treated with Aβ42, but not with Aβ40, and we
confirmed that only Aβ42 was accumulated in lyso-
somes using confocal microscopy as previously de-
scribed [36-38]. Therefore, our experimental system
works, but further studies will be needed to clarify the
relationship between Aβ deposition, phosphorylation,
and protein degradation using primary neuronal cells
or an in vivo system.
p62 is physiologically expressed in most organs, and
can be incorporated into a wide spectrum of ubiquitin-
positive inclusions in neurodegenerative diseases [39-41].
In AD, p62 is extensively accumulated in NFTs [40].
Similarly, we showed that an anti-P-S349 antibody spe-
cifically reacted with NFTs, whereas an anti-P-S403antibody recognised dystrophic neurites in amyloid pla-
ques. Both pathological lesions (NFTs and dystrophic
neurites) are composed of hyper-phosphorylated tau.
Babu et al. reported that p62 interacts with ubiquiti-
nated tau through its UBA domain and helps degrade
tau by a ubiquitin-proteasome process [42]. As de-
scribed above, phosphorylated p62 at S403 is highly in-
volved in the degradation of ubiquitinated molecules by
the autophagy-lysosome system [22]. Taken together,
phosphorylated tau is potentially delivered to the prote-
asome as well as the autophagy-lysosome system together
with p62. Importantly, NFTs were immunonegative for
P-S403. These results suggest that P-S349 or P-S403 on
p62 is able to distinguish hyper-phosphorylated tau in
NFTs from that in dystrophic neurites.
Conclusion
In conclusion, we provide evidence that S349 on p62 is
efficiently phosphorylated following inhibition of the
Tanji et al. Acta Neuropathologica Communications 2014, 2:50 Page 13 of 14
http://www.actaneurocomms.org/content/2/1/50proteasome and of autophagy. Because p62 is highly in-
volved in protein degradation systems as well as the
pathogenesis of several diseases, these results suggest
that post-translational modifications of p62 have pivotal
roles in the progression of neurodegeneration in AD.
Additional files
Additional file 1: Figure S1. SH-SY5Y cells were treated with Epo,
MG132 (MG), and Lactacysin (Lac) for the indicated hours. Immunoblotting
analysis demonstrates that all treatments induced phosphorylation of S349.
LC3-II level is gradually increased in cells treated with proteasome inhibitors.
Additional file 2: Figure S2. Reactivity of P-S349 antibody for mutated
p62. Transfection with p62-EGFP (wild type, phosphorylation-mimetic or
defective mutants) was performed and analysed by immunoblotting. P-S349
antibody reacts with p62-S349E and wild type. Additionally, endogenous
p62 is slightly phosphorylated in cells with p62-S349E and wild type, but not
p62-S349A. Anti-GFP antibody recognises p62-EGFP and mutants. Anti-p62
antibody reacts with endogenous p62 as well as p62-EGFP and mutants.
Additional file 3: Figure S3. The effect of transient transfection on
p62 phosphorylation. HeLa cells were treated with transfection
reagent alone, Fugene 6 or Lipofectamine 2000 (Lipo) for 24 h.
Confocal immunofluorescence analysis shows that total p62 (blue)
forms cytoplasmic bodies, and P-S349 signals (green) are detected in
these inclusions. Endogenous Keap1 (red) is weakly detected in the
cytoplasm. The Keap1 signal is enhanced in cells transfected with Lipo
and is partially colocalised in p62 inclusions. The islet panels indicate
higher magnification. Scale bar = 20 μm.
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